
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax SA is positioned favorably in the biotechnology sector, particularly with its drug candidate obefazimod, which is currently undergoing Phase 3 clinical trials for ulcerative colitis, a chronic inflammatory disease. The expected growth of the ulcerative colitis market, projected to increase from $9.2 billion in 2025 to $21.2 billion by 2032, coupled with significant clinical data demonstrating the effectiveness of obefazimod, supports a strong outlook for the company. Furthermore, the anticipated annual sales of approximately €9.5 billion ($11 billion) by 2039 and a compound annual growth rate (CAGR) of around 7.8% underscore the potential for substantial financial returns as the global inflammatory bowel disease market expands.
Bears say
Abivax's stock outlook appears negative due to several concerning factors, primarily related to its clinical trial outcomes and competitive positioning. The company's obefazimod drug candidate has demonstrated a disappointing placebo-adjusted clinical remission rate of less than 20%, raising substantial concerns over its market potential and diminishing the interest from potential acquirers. Additionally, the limited patent protection, expiring in 2035 with hopes for an extension to 2039, along with higher clinical risks and possible negative comparisons to competitor benchmarks, suggests a perilous environment for maintaining franchise value and future growth.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares